Mounjaro, Lilly and European Union

Eli Lilly’s Mounjaro Won’t Have Separate Sleep Apnea Label in EU
Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with regulators saying Friday that use of the drug is already covered in its approval as a weight-loss medicine.
EU drugs regulator backs Mounjaro's sleep apnea use without fresh approval for Lilly
The European Medicines Agency has allowed Eli Lilly to update the product label of its weight-loss drug Mounjaro to show it has benefit in treating a sleep disorder without approving it specifically for the disease,
Lilly's Mounjaro does not need separate indication for sleep apnea, EMA panel determines
An expert panel of the EU drug regulator, the European Medicines Agency (EMA), has determined that Eli Lilly's (NYSE:LLY) weight-loss drug Mounjaro (tirzepatide) does not need a separate indication for the treatment of obstructive sleep apnea (OSA).
Eli Lilly to test weight loss drug Zepbound to treat addiction
Weight loss injections have become a popular choice to help people curb their appetite, but can they curb addiction, as well?
EMA says Lilly's weight-loss drug does not need separate approval for sleep apnea
The European Medicines Agency said on Friday Eli Lilly's weight-loss drug Mounjaro does not need a separate approval for the treatment of a sleep disorder called obstructive sleep apnea (OSA). The hea
Eli Lilly Will Sell Zepbound Through Telehealth Company Ro in a Swipe at Legal Copycats
Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the ...
24/7 Wall St19h
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 491.86% and ...
Eli Lilly Stock Could Have a Huge Growth Catalyst in Early 2025
Eli Lilly (NYSE: LLY) may seem like an expensive stock to invest in right now. Its $720 billion market capitalization also ...
STAT2d
Eli Lilly strikes Zepbound deal with Ro, amid questions about future of compounded GLP-1s
Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.
The Washington Post10d
Zepbound tops Wegovy for weight loss in Eli Lilly study
Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo ...
Business Insider1d
Buy Rating for Eli Lilly & Co: Strategic Developments and Promising Oncology Pipeline Drive Optimism
Jefferies analyst Akash Tewari maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $994.00. Pick the best stocks and maximize your portfolio: Discover ...
STAT2d
Eli Lilly to test obesity medications as treatments for alcohol and drug addiction, CEO says
Eli Lilly will start studying its obesity products as treatments for alcohol and drug abuse, making it the first major ...
Eli Lilly Stock Just Got Even Sweeter. Here's Why It's Worth Buying Now
Eli Lilly just shared some new information. That data suggests it has an advantage against Novo Nordisk in a key market.
Crain's New York2d
Eli Lilly taps Ro to help it sell a cheaper version of its weight-loss drug
Eli Lilly is partnering with the Flatiron-based telehealth company Ro to sell a cheaper version of its popular weight-loss ...
Fierce Healthcare2d
Ro teams up with Eli Lilly to offer single-dose vials of weight loss drug Zepbound
Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss ...
NBC Los Angeles3d
Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly
It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...
Daily6h
ELi Lilly Omvoh recommended by CHMP for approval in EU for adults with moderately to severely active Crohn's disease
Indianapolis: Eli Lilly and Company has announced that the European Medicines Agency's (EMA) Committee for Medicinal Products ...